Claire Louvar-canga, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4455 S 108th St, Greenfield Highlands Walk-in Clinic, Greenfield, WI 53228 Phone: 414-427-5350 Fax: 414-427-5311 |
Dr. Chaksau Sharma, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4600 W Loomis Rd Ste 130, Greenfield, WI 53220 Phone: 414-389-4900 |
Nathan Burkle, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4455 S 108th St, Greenfield, WI 53228 Phone: 414-427-5310 Fax: 414-427-5311 |
Ms. Sussy Lynn King, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6901 W Edgerton Ave, Greenfield, WI 53220 Phone: 414-325-5244 |
Hector M Lopez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4931 S 27th St, Suite 200, Greenfield, WI 53221 Phone: 414-546-3400 Fax: 414-546-3500 |
Barbara Ann Hummel, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4811 S 76th St Ste 201, Greenfield, WI 53220 Phone: 414-604-0520 Fax: 414-604-0525 |
News Archive
A new study in the Journal of the National Cancer Institute indicates that survivors of uterine cancer are more likely to experience cardiovascular problems years after treatment.
Contrast agents can help to make these images even clearer and allow physiological processes to be followed in real time. Conventional gadolinium complexes currently used as MRI contrast agent cannot reveal anatomic structures.
Chemists at Tufts University's School of Arts and Sciences, collaborating with PerkinElmer and UCL (University College London), have witnessed atoms of one chemical element morph into another for the first time ever - a feat that produced an unexpected outcome that could lead to a new way to safely treat cancer with radiation.
ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.
› Verified 6 days ago